Cite
REAL‐WORLD TREATMENT PATTERNS, DISCONTINUATION AND CLINICAL OUTCOMES IN PATIENTS WITH B‐CELL LYMPHOPROLIFERATIVE DISEASES TREATED WITH BTK INHIBITORS IN CHINA.
MLA
Yan, Y., et al. “Real‐World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B‐Cell Lymphoproliferative Diseases Treated with Btk Inhibitors in China.” Hematological Oncology, vol. 41, June 2023, pp. 734–36. EBSCOhost, https://doi.org/10.1002/hon.3165_587.
APA
Yan, Y., Lv, R., Wang, T., Yu, Y., Huang, Y., Xiong, W., Li, Y., Sui, W., Wang, Q., Huang, W., An, G., Zou, D., Wang, J., Qiu, L., & Yi, S. (2023). Real‐World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B‐Cell Lymphoproliferative Diseases Treated with Btk Inhibitors in China. Hematological Oncology, 41, 734–736. https://doi.org/10.1002/hon.3165_587
Chicago
Yan, Y., R. Lv, T. Wang, Y. Yu, Y. Huang, W. Xiong, Y. Li, et al. 2023. “Real‐World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B‐Cell Lymphoproliferative Diseases Treated with Btk Inhibitors in China.” Hematological Oncology 41 (June): 734–36. doi:10.1002/hon.3165_587.